Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunosuppressive agent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Immunosuppressive agent. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-004804-77 Sponsor Protocol Number: 1262_OPBG_2018 Start Date*: 2018-07-10
    Sponsor Name:BAMBINO GESU' CHILDREN'S HOSPITAL
    Full Title: A prospective study to assess safety and efficacy of the use of bone-marrow derived MESenchymal stromal cells as immunomodulatory therapy for children and young adults with severe and difficult-to-...
    Medical condition: severe multi-relapsing or steroid-dependent INS.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005604-14 Sponsor Protocol Number: AIFA TX Start Date*: 2006-12-19
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropathy prevention of mycophenolate mofetil versus azathioprine as the sole immunosuppressive therapy f...
    Medical condition: kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    6.1 10023439 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003119-13 Sponsor Protocol Number: 14/0172 Start Date*: 2015-02-11
    Sponsor Name:Joint Research Office- UCL
    Full Title: Can simvastatin significantly reduce the amount of immunosuppressive medication required by patients with sight threatening uveitis? A phase IIb, single site, randomized, placebo controlled, double...
    Medical condition: Uveitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021428 - Immune system disorders 10062016 Immunosuppression PT
    19.1 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000973-69 Sponsor Protocol Number: 0468H1-318-WW Start Date*: 2005-04-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Randomized, Open-Label, Comparative Evaluation of the Safety and Efficacy of Sirolimus versus Cyclosporine when Combined in a Regimen Containing Basiliximab, Mycophenolate Mofetil, and Corticoste...
    Medical condition: The rationale for the present study is to assess whether a CNI-free regimen including antibody induction, sirolimus, and mycophenolate mofetil (MMF) results in improved long-term renal function wit...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Prematurely Ended) AT (Completed) GB (Completed) CZ (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000935-27 Sponsor Protocol Number: 0468H1-313-EU Start Date*: 2005-06-15
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.Clinical Research & Development Department
    Full Title: A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipi...
    Medical condition: Liver allograft recipients under maintenance therapy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-002643-18 Sponsor Protocol Number: REDUCE Start Date*: 2018-09-04
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosu...
    Medical condition: Immunosuppression after kidney transplantion in elderly patients ≥65 years of age
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10062016 Immunosuppression PT
    20.0 10021428 - Immune system disorders 10054990 Immunodeficiency secondary to organ transplantation LLT
    20.0 100000004863 10074474 Transplantation complications HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001774-27 Sponsor Protocol Number: AISSM03 Start Date*: 2005-05-23
    Sponsor Name:AISSM ONLUS
    Full Title: CAMPATH-1H AS IMMUNOSUPPRESSIVE AGENT IN MDS PATIENTS MULTICENTRIC PILOT STUDY
    Medical condition: In this study we want to assess the potential of CAMPATH-1H as an immunosuppressive agent in a series of selected MDS patients, because T lymphocytes are thought to play an important role in the ...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028536 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005177-21 Sponsor Protocol Number: HGS1006-C1056 Start Date*: 2007-05-29
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042945 Systemic lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) AT (Completed) CZ (Completed) ES (Completed) SK (Completed) SE (Completed) NL (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000962-14 Sponsor Protocol Number: CCM-RNT-202101 Start Date*: 2021-07-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005238-11 Sponsor Protocol Number: IM103-010 Start Date*: 2007-01-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Belatacept Conversion Trial in Renal Transplantation
    Medical condition: Subjects who received a kidney transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002978-52 Sponsor Protocol Number: CNTO1959HDS2002 Start Date*: 2019-07-16
    Sponsor Name:Universitair Medisch Centrum Groningen
    Full Title: Guselkumab for hidradenitis suppurativa, a mode of action study.
    Medical condition: Hidradenitis suppurativa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005335-83 Sponsor Protocol Number: OUS-PTx-01 Start Date*: 2013-04-05
    Sponsor Name:Oslo University Hospital Rikshospitalet
    Full Title: A Randomized Open-label Study: Efficacy and safety of basiliximab combined with tacrolimus, mycophenolate and low-dose corticosteroids vs thymoglobulin, tacrolimus, mycophenolate and high-dose co...
    Medical condition: The only indication for pancreas-transplantation (PTx) is advanced and/or badly controlled diabetes mellitus. Patients who have developed renal insufficiency due do diabetic nephropathy may be cand...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10052278 Renal and pancreas transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022128-63 Sponsor Protocol Number: LX211-11 Start Date*: 2011-03-16
    Sponsor Name:Lux Biosciences, Inc.
    Full Title: A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Non-Infectious Uveitis Involving the Inte...
    Medical condition: Non-Infectious Intermediate, Posterior or Pan-uveitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) GB (Completed) NL (Ongoing) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005390-36 Sponsor Protocol Number: UoL001109 Start Date*: 2016-02-17
    Sponsor Name:The University of Liverpool
    Full Title: Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a str...
    Medical condition: Behcets Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-002987-29 Sponsor Protocol Number: BT–L-CsA–303–FU Start Date*: 2020-02-12
    Sponsor Name:Zambon SpA
    Full Title: An Open Label Follow-Up Study to Evaluate the Long Term Safety and Efficacy of L-CSA in Patients with a Diagnosis of CLAD-BOS after they have completed the participation to BOSTON 1 and BOSTON 2 st...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single or post Double Lung Transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002190-37 Sponsor Protocol Number: P140302 Start Date*: 2015-10-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in patients with Behçet disease : STELABEC
    Medical condition: Behçet disease STELABEC-1: patients with oral ulcers STELABEC-2 : patients with active posterior uveitis or panuveitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000725-12 Sponsor Protocol Number: Cx601-0303 Start Date*: 2017-08-08
    Sponsor Name:TiGenix, S.A.U.
    Full Title: A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem ce...
    Medical condition: Perianal fistulising Crohn´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10002156 Anal fistula PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022941-72 Sponsor Protocol Number: PMR-EC-1503 Start Date*: Information not available in EudraCT
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT ...
    Medical condition: Prophylaxis of heart transplant rejection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050432 Prophylaxis against heart transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000078-65 Sponsor Protocol Number: Rituximab Start Date*: 2007-01-17
    Sponsor Name:Karolinska University Hospital
    Full Title: Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
    Medical condition: Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036102 Polymyositis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003279-23 Sponsor Protocol Number: MOMEL27 Start Date*: 2020-01-13
    Sponsor Name:Radboudumc
    Full Title: Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY)
    Medical condition: Stage IV or unresectable stage III, BRAFV600E/K mutation positive melanoma, naïve for BRAF/MEK, PD-1/PD-L1 or CTLA-4 targeting therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 01:38:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA